Genoway (ALGEN)
Euronext Paris · France · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 2.200 |
|---|---|
| 52-week range | 2.010 – 2.880 |
| Return, 1 month / 3 months | −8.3% / −10.9% |
| Return, 1 year / 3 years | −20.6% / −44.6% |
| Trend | Below its 200-day average |
| RSI (14) | 40 |
| Volatility (1 year) | 39.8% |
| Worst drawdown (1 year) | -23.6% |
| Average daily value traded | 0.01M EUR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Genoway is a French biotechnology company based in Lyon that creates custom genetically modified animal models, chiefly mice and rats, for research. It provides services such as gene targeting, transgenesis, phenotyping and the development of preclinical models. Its customers are pharmaceutical companies, biotechnology firms and academic research laboratories that use these models to study disease and test candidate treatments. The company also offers related services in model design and breeding for life-science research.
On this site Genoway appears as a stock on the Euronext Paris (France), code ALGEN, with prices in euros (EUR). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Genoway (ALGEN) trades on the Euronext Paris in France. It last closed at EUR 2.200 on 23 October 2026.
Its price-based Market X-Ray is 51 out of 100 (a fair price profile), ranking 314 of 625 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 20.6% and over the last three months it fell 10.9%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Paris
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 57 · Fair | Mixed trend against its averages. | |
| Above 200-day average | -9.3% | ||
| From 52-week high | -20.6% | ||
| Momentum | 43 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -10.9% | ||
| 6-month return | -12.0% | ||
| 12-month return, skipping the last month | -13.4% | ||
| Stability (higher is calmer) | 61 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 39.8% | ||
| Worst drawdown, 1 year (smaller is calmer) | -23.6% | ||
| Liquidity | 40 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.01M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Momentum: Lagging most stocks on this exchange.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +2.3% |
|---|---|
| 1 month | −8.3% |
| 3 months | −10.9% |
| 6 months | −12.0% |
| 1 year | −20.6% |
| 3 years | −44.6% |
| 5 years | −42.3% |
Signals
| 50-day / 200-day average | 2.373 / 2.424 |
|---|---|
| Golden / death cross (60 days) | Death, 16 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.097 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Paris; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.